Mod­er­na jumps in­to piv­otal pack with promis­ing RSV da­ta as big ri­vals face off in megablock­buster race

There’s a foot race de­vel­op­ing for the lead of a multi­bil­lion-dol­lar vac­cine mar­ket. And once again, Mod­er­na $MR­NA promis­es to be right in the thick of things as some of the biggest block­buster play­ers in bio­phar­ma hus­tle to­ward the fin­ish line.

Af­ter the mar­ket closed on Tues­day, the big biotech, which has been in the van­guard of the mR­NA rev­o­lu­tion on Covid vac­cines, put out word that it had aced its piv­otal tri­al for a new RSV vac­cine dubbed mR­NA-1345 among old­er peo­ple above the age of 60. Mod­er­na CEO Stéphane Ban­cel head­lined the news with a clear­ly sta­tis­ti­cal­ly sig­nif­i­cant ef­fect of­fer­ing 83.7% ef­fi­ca­cy in pre­vent­ing low­er res­pi­ra­to­ry tract dis­ease among peo­ple with two or more symp­toms of dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER